Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 5, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions
Corneal Scar
Interventions
BIOLOGICAL

CSB-001 Ophthalmic Solution 0.1%

CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)

Trial Locations (7)

23502

RECRUITING

Virginia Eye Consultants, Norfolk

46260

RECRUITING

Francis Price Jr, MD, Indianapolis

46290

RECRUITING

Midwest Cornea Associates, LLC, Carmel

55305

RECRUITING

Minnesota Eye Consultants, Minnetonka

78212

RECRUITING

Stuart A. Terry, MD PA, San Antonio

92354

RECRUITING

Loma Linda University Eye Institute, Loma Linda

97210

RECRUITING

Legacy Devers Eye Institute, Portland

Sponsors
All Listed Sponsors
lead

Claris Biotherapeutics, Inc.

INDUSTRY